Advaccine Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
191
- Latest Deal Type
-
IPO
- Investors
-
15
Advaccine General Information
Description
Developer of viral vaccine technology intends to serve diabetes patients. The company currently has vaccines for hepatitis B, respiratory syncytial virus, type 1 diabetes and coronavirus in their research pipeline, enabling healthcare providers to deliver effective treatments to patients.
Contact Information
Website
www.advaccine.comCorporate Office
- No. 18 Qingqiu Street, Suzhou Industrial Park
- Suzhou, Jiangsu
- China
Corporate Office
- No. 18 Qingqiu Street, Suzhou Industrial Park
- Suzhou, Jiangsu
- China
Advaccine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. IPO | 28-Feb-2023 | Completed | Generating Revenue | |||
| 8. IPO | 26-Oct-2021 | Cancelled | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 26-Mar-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 27-Nov-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 30-Sep-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 14-Sep-2020 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 18-May-2020 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 26-Feb-2020 | $5.73M | $8.63M | Completed | Generating Revenue | |
| 1. Later Stage VC | 31-Mar-2017 | $2.9M | $2.9M | Completed | Generating Revenue |
Advaccine Patents
Advaccine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018229733-A1 | Immuno-biomarkers distinguish responsiveness versus non-responsiveness during immunotherapeutic treatments | Inactive | 16-Jun-2017 | ||
| CA-2937970-A1 | Immunotherapeutic composition, method of treatment, and method of diagnosis | Inactive | 11-Feb-2014 | ||
| AU-2015218098-A1 | Immunotherapeutic composition, therapeutic method and diagnostic method | Inactive | 11-Feb-2014 | ||
| AU-2018200638-A1 | Immunotherapeutic composition, therapeutic method and diagnostic method | Inactive | 11-Feb-2014 | ||
| EP-3106174-A1 | Immunotherapeutic composition, therapeutic method and diagnostic method | Inactive | 11-Feb-2014 | A61K38/20 |
Advaccine Signals
Advaccine Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Goldstream Investment | Corporation | Minority | ||
| Hony Capital | PE/Buyout | Minority | ||
| Wosheng Investment | Venture Capital | Minority | ||
| Dunhong Capital Management | PE/Buyout | Minority | ||
| Red Horse Investment Group | Growth/Expansion | Minority |
Advaccine FAQs
-
When was Advaccine founded?
Advaccine was founded in 2009.
-
Where is Advaccine headquartered?
Advaccine is headquartered in Suzhou, China.
-
What is the size of Advaccine?
Advaccine has 191 total employees.
-
What industry is Advaccine in?
Advaccine’s primary industry is Drug Discovery.
-
Is Advaccine a private or public company?
Advaccine is a Private company.
-
What is Advaccine’s current revenue?
The current revenue for Advaccine is .
-
How much funding has Advaccine raised over time?
Advaccine has raised $166M.
-
Who are Advaccine’s investors?
Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, and Red Horse Investment Group are 5 of 15 investors who have invested in Advaccine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process